Valuation: MacroGenics, Inc.

Market Cap 262M 230M 217M 198M 370M 25.14B 373M 2.6B 1.01B 12.82B 986M 964M 41.56B P/E 2026 *
-2.64x
P/E 2027 * -2.51x
Enterprise Value 262M 230M 217M 198M 370M 25.14B 373M 2.6B 1.01B 12.82B 986M 964M 41.56B EV / Sales 2026 *
2.43x
EV / Sales 2027 * 2.9x
Free-Float
96.52%
Yield 2026 *
-
Yield 2027 * -
1 day-7.65%
1 week-6.62%
Current month-4.51%
1 month-5.22%
3 months-18.76%
6 months+30.48%
Current year+136.65%
1 week 3.8
Extreme 3.805
4.2
1 month 3.8
Extreme 3.805
4.49
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.98965
21.88
5 years 0.99
Extreme 0.98965
22.68
10 years 0.99
Extreme 0.98965
36.48
Manager TitleAgeSince
Chief Executive Officer 53 2025-08-12
Director of Finance/CFO 59 2008-04-30
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 2001-08-31
Director/Board Member 53 2025-08-12
Director/Board Member 62 2004-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/19/26 Sell

General Counsel

-31,105 0.0489%
8/17/26 Exercice

Chief Technology Officer

80,000 0.1259%
5/19/26 Free

Director

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
-7.65%-6.62%+129.52%-17.17% 262M
+0.06%+7.20%+54.04%+111.13% 74.27B
-2.29%-2.68%+32.41%+75.07% 61.21B
+0.28%+7.27%+31.74%+23.80% 27.55B
-2.07%-3.07%-18.27%+360.90% 26.38B
-2.54%+2.71%+0.16%-4.55% 25.34B
+0.57%+3.66%+25.59%-9.08% 20.84B
-1.47%+4.46%-8.09%+513.33% 14.94B
+1.29%-2.49%+163.31%+333.06% 15.17B
-2.39%-0.12%+42.45%+159.78% 14.41B
Average -1.63%+3.08%+45.29%+154.63% 28.04B
Weighted average by Cap. -0.98%+3.08%+35.42%+134.61%

Financials

2026 *2027 *
Net sales 108M 94.96M 89.27M 81.61M 153M 10.36B 154M 1.07B 416M 5.28B 406M 397M 17.13B 90.61M 79.53M 74.75M 68.35M 128M 8.68B 129M 898M 348M 4.43B 340M 333M 14.35B
Net income -88.7M -77.85M -73.18M -66.91M -125M -8.5B -126M -879M -341M -4.33B -333M -326M -14.05B -138M -121M -114M -104M -195M -13.23B -196M -1.37B -530M -6.74B -519M -507M -21.86B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates from its proprietary suite of antibody technology platforms. It is developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which are referred to as DART and TRIDENT molecules). It has multiple proprietary product candidates. These include three clinical-stage ADCs incorporating a novel topoisomerase I inhibitor (TOP1i)-based linker-payload: MGC026, which targets B7-H3; MGC028, which targets ADAM9, and MGC030, which is directed against an undisclosed target. It is also developing lorigerlimab, a clinical-stage bispecific DART molecule targeting the immune checkpoint receptors PD-1 and CTLA-4. In addition, it is also developing multiple preclinical-stage ADC and next-generation T-cell engager programs.
Employees
293
Date Price Change Volume
26-09-23 US$3.805 -7.65% 423,903
26-09-22 US$4.120 0.00% 377,359
26-09-21 US$4.120 -0.48% 310,497
26-09-18 US$4.140 +0.24% 873,940
26-09-17 US$4.130 +1.23% 438,002
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.120USD
Average target price
8.000USD
Spread / Average Target
+94.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!